Does nicotine save users from contracting the coronavirus / COVID-19, or downsize its impact once it’s in the body? These are massive —and highly controversial questions. we would get solid answers shortly. A clinical trial is an attempt to begin in France, providing nicotine patches to COVID-19 patients and measuring the results. The trial has intended by the celebrated Pasteur Institute neurobiologist Jean-Pierre Changeux , an expert on the cholinergic system (which includes the nicotinic receptors). Most COVID-19 patient data has measured the number of infected smokers, but has not identified smokeless tobacco or e-cigarette users, it’s possible that some component in tobacco is exerting a protective effect. But the interaction between nicotine and receptors used for access to the organs by the coronavirus is the only the hypothesis that has so far been assumed by researchers, and it seems the most probable. ...
Comments
Post a Comment